Last reviewed · How we verify
NCT04941222: PEPINO
Cost-utility Analysis of the Use of the Paro Robotic Seal by Elderly Patients With Moderate or Severe Cognitive Disorders in Institutions: a Randomised Study.
NA trial testing With robotic seal "PARO" in Cognitive Impairment in 33 participants. Terminated before completion.
5 April 2023
Quick facts
| Lead sponsor | Centre Hospitalier Departemental Vendee |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 33 |
| Start date | 29 July 2021 |
| Primary completion | 5 April 2023 |
| Estimated completion | 5 April 2023 |
| Sites | 1 location across France |
Drugs / interventions tested
- With robotic seal "PARO"
Conditions studied
- Cognitive Impairment — all drugs for Cognitive Impairment →
Sponsor
Centre Hospitalier Departemental Vendee
Who can join
70 and older, any sex, with Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Many residents from establishments for dependent elderly people (EHPAD) have memory disorders with behavioural problems such as agitation, aggression and anxiety, which make it difficult to assist them on a daily basis. Studies have proven the beneficial effect of the therapeutic seal robot PARO® in behavioural disorders. The present project aims to complement these data with a medico-economic study. At present, the only study of this type has been carried out in Australia, and is not transposable to France.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04941222
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cognitive Impairment
Currently open trials in the same condition.
- NCT07504276 — Tele-Rehabilitation vs Conventional Rehabilitation for Cognitive Improvement in Stroke Survivors. · NA · recruiting
- NCT07396779 — Cognitive Task-Based Walking Effects on Cognition, Mood, Sleep, and Quality of Life in Older Adults With Brain Fog · NA · active not recruiting
- NCT07084831 — A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment i · Phase 3 · recruiting
- NCT07125378 — Living Independence Through Functional Training · Phase 1, PHASE2 · recruiting
- NCT07268079 — Validation of the VIRADIA App for Neurological and Cognitive Diagnostics in Virtual Reality · recruiting
Other Centre Hospitalier Departemental Vendee trials
Trials by the same sponsor.
- NCT07489820 — Evaluation of the Efficacy of Negative Pressure Wound Therapy on Perineal Healing Following Abdominoperineal Amputation · NA · not yet recruiting
- NCT07313293 — Impact of Foot Reflexology on Nausea After Obesity Surgery · NA · recruiting
- NCT07314632 — Prospective Study in Laser Treatment of Pilonidal Cysts · recruiting
- NCT07340060 — Statistical Association Between Bicarbonate Levels and Death or Admission to Intensive Care Within 48 Hours in Patients · recruiting
- NCT07228767 — Assessment of Surgeons' Mental Fatigue Based on Operating Time · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04941222 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Departemental Vendee
- Last refreshed: 23 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04941222.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing